| Westgold Resources Limited (WGX) ORDINARY FULLY PAID |
Materials |
$5,041 |
December 2025 Quarterly Results
|
21 Jan 2026 9:01AM |
$6.870 |
$5.360 |
fallen by
21.98%
|
|
WGX - Price-sensitive ASX Announcement
Full Release
Key Points
- Record quarterly gold production of 111,418oz in Q2 FY26.
- Group AISC increased to A$3,500/oz due to higher OPA volumes.
- Cash and bullion reserves grew by A$182 million to A$654 million.
- Company remains unhedged and focuses on operational improvements.
- Ongoing portfolio optimization with divestment of non-core assets.
- Planned demerger of Reedy’s and Comet assets into Valiant Gold Limited.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Algorae Pharmaceuticals Limited (1AI) ORDINARY FULLY PAID |
Health Care |
$19 |
$3 million Debt Facility Secured with ScotPac
|
21 Jan 2026 9:01AM |
$0.018 |
$0.010 |
fallen by
47.22%
|
|
1AI - Price-sensitive ASX Announcement
Full Release
Key Points
- $3.0 million debt finance facility secured with ScotPac.
- Facility is revolving and flexible with interest charged only on amounts utilized.
- Non-dilutive financing complements existing cash reserves.
- Supports expansion of Algorae's revenue-generating operations across ANZ.
- The facility is receivables-based with a 24-month initial term.
- Interest rate set at BBSY + 6.70%.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Noxopharm Limited (NOX) ORDINARY FULLY PAID |
Health Care |
$15 |
HERACLES clinical trial successfully completed
|
21 Jan 2026 9:00AM |
$0.078 |
$0.049 |
fallen by
37.18%
|
|
NOX - Price-sensitive ASX Announcement
Full Release
Key Points
- HERACLES clinical trial successfully completed.
- Final multiple-dose cohort of SOF-SKN™ finished.
- No clinically relevant issues found; treatment deemed safe.
- Phase II-enabling studies and drug scale-up to begin soon.
- Potential applications for SOF-SKN in autoimmune diseases such as lupus and psoriasis.
- Sofra technology platform aimed at inflammatory and autoimmune diseases.
- Global CLE market is worth over US$3.3 billion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Regal Asian Investments Limited (RG8) ORDINARY FULLY PAID |
Financials |
$290 |
Update - Notification of buy-back - RG8
|
21 Jan 2026 9:00AM |
$2.970 |
$2.070 |
fallen by
30.30%
|
|
| Regal Partners Global Investments Limited (RG1) ORDINARY FULLY PAID |
Financials |
$556 |
Update - Notification of buy-back - RG1
|
21 Jan 2026 9:00AM |
$2.430 |
$2.400 |
fallen by
1.23%
|
|
| St George Mining Limited (SGQ) ORDINARY FULLY PAID |
Materials |
$268 |
US Strategic Alliance for Rare Earths at Araxa
|
21 Jan 2026 9:00AM |
$0.125 |
$0.057 |
fallen by
54.40%
|
|
SGQ - Price-sensitive ASX Announcement
Full Release
Key Points
- St George Mining Limited has extended its strategic alliance with US-based REalloys for the rare earths resource at the Araxá Project in Brazil.
- The Araxá Project boasts a high-grade rare earths resource, the largest and highest-grade carbonatite-hosted deposit in South America.
- A Memorandum of Understanding was signed to potentially secure a long-term offtake contract for up to 40% of the Araxá Project's rare earths production.
- The collaboration aims to optimize the processing flowsheet for rare earths production at Araxá, aligning with REalloys' magnet manufacturing.
- St George Mining is engaging with the US government for potential commercial arrangements to support the Araxá Project.
- REalloys is focused on creating a fully integrated mine to magnet solution for North American supply chain independence.
- The alliance aims to boost US rare earths independence and supply, with REalloys having secured several strategic deals to bolster capabilities in rare earths.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Green & Gold Minerals Limited (GG1) ORDINARY FULLY PAID |
Materials |
$5 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
21 Jan 2026 8:59AM |
$0.180 |
$0.080 |
fallen by
55.56%
|
|
GG1 - Price-sensitive ASX Announcement
Full Release
Key Points
- High-grade drill results from Mt Wandoo support gold development strategy.
- Potential for resource expansion identified at depth and in parallel structures.
- Discussions commenced for toll treatment with Mungana Mill.
- Cash and cash equivalents decreased to $3,483k.
- Payments to related parties totaled $112k.
- Exploration and evaluation expenditure was $1.23 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cadence Opportunities Fund Limited (CDO) ORDINARY FULLY PAID |
Financials |
$39 |
Update - Notification of buy-back - CDO
|
21 Jan 2026 8:58AM |
$2.070 |
$2.120 |
risen by
2.42%
|
|
| Australian Strategic Materials Limited (ASM) ORDINARY FULLY PAID |
Materials |
- |
Investor Presentation - Energy Fuels to acquire ASM
|
21 Jan 2026 8:58AM |
$0.725 |
$1.170 |
risen by
61.38%
|
|
ASM - Price-sensitive ASX Announcement
Full Release
Key Points
- Scheme implementation deed between ASM and Energy Fuels.
- Energy Fuels to acquire ASM for A$1.60 per share.
- Establishment of a large REE producer outside China.
- Benefits include Western supply chain, funding capacity, and risk reduction.
- White Mesa Mill in Utah as a key facility.
- Transaction completion expected by 30 June 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Strategic Materials Limited (ASM) ORDINARY FULLY PAID |
Materials |
- |
Energy Fuels to acquire Australian Strategic Materials
|
21 Jan 2026 8:58AM |
$0.725 |
$1.170 |
risen by
61.38%
|
|
ASM - Price-sensitive ASX Announcement
Full Release
Key Points
- Scheme Implementation Deed between ASM and Energy Fuels.
- Conditions precedent for acquisition outlined.
- Court approval and shareholder meetings planned.
- Obligations and responsibilities of both parties detailed.
- Provisions for representations and warranties included.
- Reimbursement fees and termination clauses specified.
- Confidentiality and exclusivity obligations discussed.
- Regulatory approvals required for transaction completion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| White Cliff Minerals Limited (WCN) ORDINARY FULLY PAID |
Materials |
$87 |
Deep Drilling Results at Danvers Points to Depth Extension
|
21 Jan 2026 8:58AM |
$0.018 |
$0.022 |
risen by
22.22%
|
|
WCN - Price-sensitive ASX Announcement
Full Release
Key Points
- White Cliff Minerals Limited reported deep drilling results.
- The drilling was conducted at the Danvers site.
- Data includes copper concentration at various depths.
- Results indicate potential depth extensions of mineralization.
- Copper percentages vary, suggesting significant presence.
- Further exploration may be warranted based on results.
- Drilling results target economic viability assessment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Anteris Technologies Ltd (AVR) CHESS DEPOSITARY INTERESTS 1:1 |
Health Care |
$123 |
Preliminary Prospectus Supplement
|
21 Jan 2026 8:57AM |
$7.290 |
$8.450 |
risen by
15.91%
|
|
AVR - Price-sensitive ASX Announcement
Full Release
Key Points
- Preliminary Prospectus Supplement for Anteris Technologies Ltd
- Common stock listed under 'AVR' on Nasdaq
- Offering involves a high degree of risk
- Details on offering price and underwriting
- Use of proceeds for business support and strategic initiatives
- Includes risk factors and future outlook
- Information on recent company developments
- Concurrent private placement information
- Material U.S. federal income tax consequences for non-U.S. holders
- Legal disclaimers and limitations on accounting firm’s liability
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Barton Gold Holdings Limited (BGD) ORDINARY FULLY PAID |
Materials |
$228 |
Further Shallow High-Grade Assays Infill Tunkillia S1/2 Pits
|
21 Jan 2026 8:57AM |
$1.320 |
$0.840 |
fallen by
36.36%
|
|
BGD - Price-sensitive ASX Announcement
Full Release
Key Points
- Barton Gold Holdings Limited announced further shallow high-grade assays from the Tunkillia S1/2 pits.
- Multiple drill holes showcased notable gold mineralization, with highlights including intersections such as 24m at 4.49 g/t gold from 127m and 38m at 1.54 g/t gold from 127m in hole TKB0435.
- The assays are part of a larger reverse circulation (RC) drilling program aimed at upgrading the Mineral Resource Estimate (MRE).
- The project is located in the Area 223 region of the Tunkillia Gold Project and is essential for Barton Gold’s strategic development plans.
- Further plans include water bore drilling followed by a Phase 2 MRE upgrade and diamond drilling.
- The company is working towards completing a high-quality pre-feasibility study (PFS) and submitting a Mining Lease application by the end of 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tivan Limited (TVN) ORDINARY FULLY PAID |
Materials |
$352 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
21 Jan 2026 8:54AM |
$0.310 |
$0.150 |
fallen by
51.61%
|
|
TVN - Price-sensitive ASX Announcement
Full Release
Key Points
- Tivan Limited's quarterly cash flow report ended 31 December 2025.
- Net cash used in operating activities was A$1,669,000.
- Net cash outflow for investing activities was A$7,043,000.
- The company raised A$15,850,000 from the issue of shares.
- Cash and cash equivalents at quarter end were A$11,923,000.
- Completion of Molyhil Project acquisition and progress on Speewah Vanadium Project.
- Details of mineral resource estimates and exploration activities included.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Regal Investment Fund (RF1) ORDINARY UNITS FULLY PAID |
Financials |
$631 |
Update - Notification of buy-back - RF1
|
21 Jan 2026 8:53AM |
$3.590 |
$3.020 |
fallen by
15.88%
|
|
| BCAL Diagnostics Limited (BDX) ORDINARY FULLY PAID |
Health Care |
$29 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
21 Jan 2026 8:53AM |
$0.125 |
$0.080 |
fallen by
36%
|
|
BDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Avantect® pancreatic and ovarian cancer tests ready for Australian launch in January 2026.
- National ethics approval received for the BREASTESTplus™ registry.
- Cash balance of $3.3 million reported as of 31 December 2025.
- Approval for a $10 million convertible note facility with $5 million committed.
- Received a $2.5 million R&D tax refund from the Australian Taxation Office.
- Continued sales and clinical engagement for the BREASTESTplus™ blood test.
- Focus on converting validated science into real-world clinical impact.
- Strengthened clinical foundation of BREASTESTplus™, with new Australian data supporting its use.
- Operational updates include securing UK regulatory approvals and international milestones for Avantect® tests.
- Financial report prepared according to Australian Accounting Standards.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Variscan Mines Limited (VAR) ORDINARY FULLY PAID |
Materials |
- |
Novales-Udias Project and Market Update
|
21 Jan 2026 8:52AM |
$0.009 |
$0.004 |
fallen by
55.56%
|
|
| AdAlta Limited (1AD) ORDINARY FULLY PAID |
Health Care |
$10 |
AdCella milestones and regulatory progress
|
21 Jan 2026 8:51AM |
$0.006 |
$0.003 |
fallen by
50%
|
|
1AD - Price-sensitive ASX Announcement
Full Release
Key Points
- AdAlta Limited announces alignment of its AdCella strategy with new US FDA manufacturing requirements.
- AdCella has paid the first milestone of US$0.5 million towards the BZDS1901 collaboration with SHcell.
- The company received an additional $0.15 million RDTI refund for FY2025 expenses related to CAR-T cell therapy.
- AdAlta's 'East to West' strategy integrates Asian T cell therapy innovations with Western markets.
- AdAlta aims to demonstrate clinical and manufacturing proof of concept for its products.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ryzon Materials Limited (RYZ) ORDINARY FULLY PAID |
Materials |
- |
Removal from the Official List
|
21 Jan 2026 8:50AM |
$0.042 |
$0.042 |
fallen by
0%
|
|
| Aristocrat Leisure Limited (ALL) ORDINARY FULLY PAID |
Consumer Discretionary |
$37,105 |
Update - Notification of buy-back - ALL
|
21 Jan 2026 8:48AM |
$56.200 |
$62.640 |
risen by
11.46%
|
|
| Astral Resources NL (AAR) ORDINARY FULLY PAID |
Materials |
$253 |
More High-Grade Gold in Kamperman Extensional Drilling
|
21 Jan 2026 8:48AM |
$0.260 |
$0.140 |
fallen by
46.15%
|
|
AAR - Price-sensitive ASX Announcement
Full Release
Key Points
- 17-hole RC drill program completed at Kamperman with high-grade results.
- 14m at 6.79g/t Au and 13m at 6.60g/t Au among significant intercepts.
- Drilling extends high-grade zones beyond current Mineral Resource.
- Diamond drilling at Theia deposit also shows high-grade intercepts.
- Results suggest potential for resource growth at Kamperman and Theia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Amaero Ltd (3DA) CHESS DEPOSITARY INTERESTS 40:1 |
Industrials |
$210 |
Non-Deal Roadshow Investor Presentation
|
21 Jan 2026 8:47AM |
$0.355 |
$0.220 |
fallen by
38.03%
|
|
| Vulcan Energy Resources Limited (VUL) ORDINARY FULLY PAID |
Materials |
$613 |
Successful production testing of first new Lionheart well
|
21 Jan 2026 8:46AM |
$4.160 |
$1.280 |
fallen by
69.23%
|
|
VUL - Price-sensitive ASX Announcement
Full Release
Key Points
- Vulcan Energy Resources Limited successfully tested the production potential of their first new Lionheart well, LSC-1b, in Germany.
- The test results confirmed a production potential range of 105 to 125 liters per second, supporting the Lionheart Field Development Plan.
- The Lionheart project aims to produce 24,000 tonnes of lithium hydroxide monohydrate annually, enough for approximately 500,000 electric vehicle batteries.
- A co-product of the project is the generation of 275 GWh of renewable power and 560 GWh of heat per year.
- The project has secured financing and is fully funded to proceed with Phase One construction and execution.
- The development includes an integrated lithium and renewable energy project over an estimated 30-year project life.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aurelia Metals Limited (AMI) ORDINARY FULLY PAID |
Materials |
$740 |
Quarterly Update and Outlook - December 2025
|
21 Jan 2026 8:44AM |
$0.290 |
$0.430 |
risen by
48.28%
|
|
AMI - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant cash flow from strong gold production.
- Federation Mine ramp-up is ahead of schedule.
- Great Cobar Copper Project and Peak Plant projects on schedule.
- Operating and growth costs are within guidance.
- Strong balance sheet with disciplined capital allocation.
- Exploration confirms extensions at key sites.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Anteris Technologies Ltd (AVR) CHESS DEPOSITARY INTERESTS 1:1 |
Health Care |
$123 |
Trading Halt
|
21 Jan 2026 8:43AM |
$7.290 |
$8.450 |
risen by
15.91%
|
|
AVR - Price-sensitive ASX Announcement
Full Release
Key Points
- Anteris Technologies Global Corp requested a trading halt effective from 21 January 2026.
- The halt is pending an announcement related to the pricing of a proposed capital raising.
- The trading halt will last until the announcement is made or normal trading resumes on 23 January 2026.
- Anteris Technologies Global Corp is listed on the Australian Securities Exchange under the ticker AVR.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
